PRECIPIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.736 USD | +1.22% |
|
+3.46% | +3.62% |
| Apr. 01 | Transcript : Precipio, Inc. - Special Call | |
| Mar. 29 | Precipio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2022 | 9.41M | Sales 2023 | 15.2M | Capitalization | 9.23M |
|---|---|---|---|---|---|
| Net income 2022 | -12M | Net income 2023 | -5M | EV / Sales 2022 | 1.12 x |
| Net cash position 2022 | 2.05M | Net cash position 2023 | 386K | EV / Sales 2023 | 0.58 x |
| P/E ratio 2022 |
-1.03
x | P/E ratio 2023 |
-1.44
x | Employees | 54 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 96.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Precipio, Inc.
More recommendations
More press releases
| 1 day | -0.66% | ||
| 1 week | +1.54% | ||
| Current month | -1.34% | ||
| 1 month | +8.36% | ||
| 3 months | +25.43% | ||
| 6 months | +1.07% | ||
| Current year | +1.69% |
1 week
6.15
6.84
1 month
6.007.00
Current year
5.007.30
1 year
4.7515.41
3 years
4.75183.60
5 years
4.75216.00
10 years
4.758 448.01
| Managers | Title | Age | Since |
|---|---|---|---|
Ilan Danieli
CEO | Chief Executive Officer | 52 | 17-06-27 |
Matthew Gage
DFI | Director of Finance/CFO | 57 | 17-06-30 |
Ayman Mohamed
CTO | Chief Tech/Sci/R&D Officer | 39 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ronald Andrews
BRD | Director/Board Member | 64 | 21-02-28 |
Kathy LaPorte
BRD | Director/Board Member | 62 | 18-08-08 |
Richard Sandberg
CHM | Chairman | 80 | 19-12-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 6.736 | +1.22% | 1,653 |
| 24-04-12 | 6.654 | +0.09% | 3,352 |
| 24-04-10 | 6.648 | +4.69% | 8,532 |
| 24-04-09 | 6.35 | -2.46% | 24,256 |
Delayed Quote Nasdaq, April 15, 2024 at 01:30 pm EDT
More quotes
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Companyâs technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Companyâs laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.69% | 9.52M | |
| -43.34% | 2.82B | |
| +7.25% | 1.78B | |
| -7.99% | 1.56B | |
| +29.09% | 1.25B | |
| -13.75% | 1.01B | |
| -23.36% | 900M | |
| -3.39% | 741M | |
| -15.07% | 701M | |
| +2.36% | 485M |
- Stock Market
- Equities
- PRPO Stock
